Africa’s Healthcare Access Gap as an Investment Thesis, Not a Charity Case

A Framing Problem, Not Just a Capital Problem

The instinct to frame African healthcare investment primarily through a development or philanthropic lens is understandable given the continent’s genuine and severe access gaps, but it consistently undersells what is actually a coherent, return-driven investment thesis, and it has probably cost the sector meaningful institutional capital that would otherwise have flowed toward it on ordinary commercial terms. A generalist allocator who encounters “African healthcare investment” framed primarily as an impact or development-finance category tends to route it toward a philanthropic or concessional-capital bucket rather than a genuine venture-return bucket — even when the underlying commercial economics would justify ordinary risk-adjusted return expectations.

The demographic backdrop alone makes the case for the latter framing: Africa’s population is growing faster than any other continent’s, its median age is by a wide margin the youngest in the world, and its urban centers are expanding at a pace that is straining every category of healthcare infrastructure — diagnostics, pharmaceutical distribution, hospital capacity, insurance and payment systems — simultaneously. That is, read plainly, a description of enormous unmet demand meeting chronically undersupplied infrastructure, which is the textbook precondition for venture-scale returns in any sector, not only healthcare.

The Regulatory Groundwork Has Already Been Laid

Regional regulatory and reimbursement infrastructure has matured considerably faster than most global investors give it credit for, and the specific frameworks matter for anyone actually underwriting deals in the region rather than observing it from a distance. Kenya’s Social Health Insurance Fund, which replaced the country’s older National Hospital Insurance Fund model, is extending formal insurance coverage to a meaningfully larger share of the population than existed even five years ago — a genuine structural shift in how healthcare gets paid for in one of East Africa’s largest economies, and one that directly expands the addressable, formally insured patient population for any healthcare business operating in the country.

The Kenya Bureau of Standards and the country’s Pharmacy and Poisons Board have built pharmaceutical quality and registration frameworks credible enough that regional and international manufacturers increasingly treat Kenya as a genuine regulatory gateway to the broader East African Community market, not merely a single-country registration exercise — meaning a manufacturer that clears Kenyan registration has a genuinely shorter, more credible path to registering the same product across neighboring East African markets than it would starting from scratch in each country individually. COMESA’s regional trade framework, while imperfect, has meaningfully reduced the friction of moving pharmaceutical and medical products across East and Southern African borders relative to a decade ago, addressing what has historically been one of the more underappreciated obstacles to building a genuinely regional, rather than single-country, African healthcare business.

The Sub-Sectors Worth Underwriting Individually

The specific sub-sectors where the access gap and the investment case align most cleanly are worth naming directly, because “African healthcare” as a single category is too broad to underwrite against usefully — the risk, return, and capital-intensity profiles across diagnostics, distribution, hospital care, and manufacturing are genuinely different businesses that happen to share a continent.

Diagnostics infrastructure — both the basic laboratory capacity many health systems still lack and the more advanced imaging and molecular diagnostic capability needed to support the oncology and precision-medicine advances discussed elsewhere in this issue — represents acute unmet need with a reasonably clear commercial path, since diagnostic testing is a recurring, volume-driven revenue model rather than a one-time capital-intensive build, and the falling genomic and molecular testing costs discussed elsewhere in this issue make this specific opportunity considerably more accessible than it would have been even five years ago.

Pharmaceutical distribution and cold-chain logistics, the unglamorous infrastructure layer that determines whether a manufactured drug actually reaches a rural clinic in usable condition, is chronically underinvested relative to its criticality and increasingly investable as e-commerce and mobile-payment infrastructure across the continent matures enough to support the last-mile logistics that pharmaceutical distribution specifically requires — the same mobile-payment rails that have made East Africa a genuine global leader in mobile money adoption are, in effect, laying the transactional infrastructure that a modern pharmaceutical distribution business can build directly on top of.

The Hospital Sector’s India Parallel

Hospital and specialty-care infrastructure sits at a genuinely interesting inflection point. Private hospital groups across Kenya, Nigeria, and increasingly other major markets have demonstrated that a well-capitalized, professionally managed private facility can achieve both strong clinical outcomes and durable commercial economics, serving a rapidly growing middle class willing and increasingly able to pay for quality care that public systems, however improving, cannot yet reliably provide at scale.

That is a familiar pattern to any investor who has tracked India’s own private hospital sector over the past two decades — a sector this fund has direct, first-hand exposure to through its work with Anjaniputra Hospitals and the broader Indian hospital-investment landscape — and the structural similarities — a large population, a growing middle class, an underfunded public system, and a private sector stepping into the resulting gap — are close enough that lessons from India’s hospital-sector build-out translate with real fidelity to several African markets, East Africa in particular. That translation is not automatic or costless; India’s hospital sector took two decades and several distinct waves of capital to reach its current scale, and an investor expecting the same outcome in East Africa on a compressed timeline is likely to be disappointed. But the underlying playbook — capital-efficient facility design, physician-recruitment and retention strategy, insurance-partnership development — is genuinely transferable knowledge, not something that has to be relearned from first principles in each new market.

The Overlooked Layer: Manufacturing and Waste

Manufacturing and waste-management infrastructure, categories that rarely appear in conventional healthcare-investment framing at all, deserve inclusion because they are direct preconditions for everything else in the sector functioning sustainably. Kenya’s Sustainable Waste Management Act and its extended producer responsibility provisions are beginning to formalize a pharmaceutical and medical-waste management sector that most health systems in the region have historically handled informally or not at all — a regulatory tailwind that is creating a genuinely new, investable services category rather than merely adding compliance cost to existing businesses, since a formalized waste-management requirement creates real demand for a specialized service provider that did not previously need to exist at scale.

That regulatory pattern — extended producer responsibility provisions creating a new compliance-driven services market — is one we track closely across our African portfolio work generally, since it has proven, in Kenya’s plastics and manufacturing sectors as much as in healthcare specifically, to be one of the more reliable sources of genuinely new investable categories emerging from the region’s regulatory maturation.

The Risks, Stated Plainly

The honest risk factors deserve equal billing rather than being waved away. Currency volatility, regulatory inconsistency across the more than fifty distinct national jurisdictions that make up the continent, and genuinely difficult last-mile logistics in less urbanized regions are real constraints that any investor underwriting African healthcare has to price in carefully, not optimistically assume away — a business model that works cleanly in Nairobi does not automatically transfer to a secondary Kenyan city, let alone across a border into Tanzania or Uganda, each with its own distinct regulatory, currency, and logistics environment.

They are also, not coincidentally, exactly the kind of structural friction that rewards a fund with genuine on-the-ground origination and diligence capability — local counsel relationships, regulatory expertise specific to individual markets, portfolio-company operational support — over a fund attempting to underwrite African healthcare deals remotely from London, New York, or even Mumbai without a genuine local presence. That friction is, in effect, a moat for the investors willing to build the local capability to navigate it, and a genuine barrier to entry for capital that would prefer to allocate to the region without doing that work.

The Thesis, Restated

The thesis we hold is not that Africa needs healthcare capital as an act of goodwill — it is that Africa’s specific combination of demographic tailwind, chronically undersupplied infrastructure, and maturing but still-developing regulatory frameworks produces exactly the conditions under which patient, well-underwritten capital has historically generated outsized returns in other emerging markets, India’s own healthcare sector prominent among them. Treating the continent’s access gap as primarily a development problem rather than primarily an investment opportunity is, at this point, simply an outdated read of the underlying economics, and it is a read we have deliberately moved away from across our own African deal work, in structure and pricing as much as in language.